MiMARK focuses on improving the accuracy and efficiency of diagnostics for endometrial cancer, which is the sixth most commonly occurring cancer in women. As with many cancers, early and accurate detection of the disease is linked to increased survival, however currently around a third of endometrial cancer patients are diagnosed at the advanced stage. By improving the technology available for the diagnosis of endometrial cancer, MiMARK hopes to improve the speed and accuracy at which women can be diagnosed and effectively treated.
Health Care, Health Diagnostics, Biomarkers
Between €1 million-€ 2.5 million
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as MiMARK? We’re happy to assist you with our Startup Sourcing service.